» Articles » PMID: 19030026

The Role of Granulocyte Macrophage-colony-stimulating Factor in Acute Intestinal Inflammation

Overview
Journal Cell Res
Specialty Cell Biology
Date 2008 Nov 26
PMID 19030026
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

An imbalance of mucosal pro- and anti-inflammatory cytokines is crucial in the pathogenesis of inflammatory bowel disease (IBD). GM-CSF influences the development of hemopoietic cells. The precise role of GM-CSF in IBD remains to be elucidated. GM-CSF gene knockout (GM-CSF(-/-)) and wild-type (Wt) mice were challenged with 2.5% dextran sulfate sodium (DSS) for 7 days. The ensued clinical and pathological changes, macrophage infiltration, colonic cytokine production, and bacterial counts were examined. DSS-treated GM-CSF(-/-) mice developed more severe acute colitis than DSS-treated Wt mice, reflected by a greater body weight loss, more rectal bleeding, and aggravated histopathological changes. More infiltrating macrophages were observed in GM-CSF(-/-), compared with Wt mice following DSS challenge, correlating with monocyte chemoattractant protein-1 (MCP-1) production. The levels of colonic IL-17 and TNF-alpha were increased significantly in GM-CSF(-/-) mice, but not in Wt mice, following DSS administration. The level of IL-6 was increased by 1.5- and 2-fold in the colon of GM-CSF(-/-) and Wt mice, respectively, following DSS challenge. No significant changes in IL-4 and IFN-gamma were detected in Wt and GM-CSF(-/-) mice following DSS treatment. The bacteria recovery from colon was increased about 15- and 5-fold, respectively, in Wt mice and GM-CSF(-/-) mice following DSS challenge. These results suggest that GM-CSF(-/-) mice are more susceptible to acute DSS-induced colitis, possibly because of an impaired gut innate immune response as a result of diminished GM-CSF.

Citing Articles

Noncoding RNAs in rheumatoid arthritis: modulators of the NF-κB signaling pathway and therapeutic implications.

Seyedi D, Espandar N, Hojatizadeh M, Mohammadi Y, Sadri F, Rezaei Z Front Immunol. 2024; 15:1486476.

PMID: 39530095 PMC: 11550995. DOI: 10.3389/fimmu.2024.1486476.


Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells.

Ohara D, Takeuchi Y, Hirota K Cell Mol Immunol. 2024; 21(11):1183-1200.

PMID: 39379604 PMC: 11528014. DOI: 10.1038/s41423-024-01218-x.


Strategies for targeting cytokines in inflammatory bowel disease.

Neurath M Nat Rev Immunol. 2024; 24(8):559-576.

PMID: 38486124 DOI: 10.1038/s41577-024-01008-6.


Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer.

Dougan M, Nguyen L, Buchbinder E, Lazarus H Cancers (Basel). 2024; 16(3).

PMID: 38339253 PMC: 10854719. DOI: 10.3390/cancers16030501.


A Versatile Intestine-on-Chip System for Deciphering the Immunopathogenesis of Inflammatory Bowel Disease.

Nguyen O, Misun P, Hierlemann A, Lohasz C Adv Healthc Mater. 2024; 13(7):e2302454.

PMID: 38253407 PMC: 11468350. DOI: 10.1002/adhm.202302454.